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Abstract
Background: Sex differences in Parkinson disease clinical features have been
reported, but few studies have examined sex influences on use of dopaminergic
medication in early Parkinson disease. The objective of this study was to test if
there are differences in the type of dopaminergic medication used and levodopa
equivalent daily dose between men and women with early Parkinson disease
enrolled in a large multicenter study of Creatine as a potential disease modifying
therapy – the National Institute of Neurological Disorders and Stroke Exploratory
Trials in Parkinson Disease Long-Term Study-1.
Methods: Baseline data of 1,741 participants from 45 participating sites were
analyzed. Participants from the United States and Canada were enrolled within five
years of Parkinson Disease diagnosis. Two outcome variables were studied: type of
dopaminergic medication used and levodopa equivalent daily dose at baseline in
the Long-Term Study-1. Chi-square statistic and linear regression models were
used for statistical analysis.
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PLOS ONE | DOI:10.1371/journal.pone.0112287 December 8, 2014 1/1 1Results: There were no statistically significant differences in the frequency of use
of different types of dopaminergic medications at baseline between men and
women with Parkinson Disease. A small but statistically significant difference was
observed in the median unadjusted levodopa equivalent daily dose at baseline
between women (300 mg) and men (325 mg), but this was not observed after
controlling for disease duration (years since Parkinson disease diagnosis), disease
severity (Unified Parkinson’s Disease Rating Scale Motor and Activities of Daily
Living Scores), and body weight.
Conclusions: In this large multicenter study, we did not observe sex differences in
the type and dose of dopaminergic medications used in early Parkinson Disease.
Further research is needed to evaluate the influence of male or female sex on use
of dopaminergic medication in mid- and late-stage Parkinson Disease.
Introduction
Sex differences in medical treatment have been reported in the pain and
cardiovascular medicine literature, with men receiving more aggressive treatment
for these conditions. [1,2] When assessing sex differences in stroke- a prevalent
neurological condition- women are less likely than men to receive thrombolytic
treatment with alteplase and are reported to have poorer stroke-related outcomes
including greater disability and lower quality of life. [3] Disparities in treatment
based on sex can have a significant impact on morbidity, mortality, and quality of
life.
Sex differences in the clinical characteristics of Parkinson Disease (PD) have
been frequently reported, however, little is known about the influence of male or
female sex on treatment for this common condition. The initial presenting sign,
severity of parkinsonian symptoms, and/or development of dyskinesia are
important considerations in clinical practice regarding choice of dopaminergic
medication in PD. In a study of 1,264 PD patients with similar disease duration,
men were found to have more severe rigidity while women had more severe
dyskinesias with treatment. [4] Another study showed that women were more
likely than men to have tremor as an initial presenting sign. [5] These sex
differences in clinical characteristics could influence the type and dose of
dopaminergic medications used in early PD. With the exception of a few studies,
the impact of male or female sex on dopaminergic medication use in PD has
remained largely unexplored.
In one study of PD subjects with disease duration of at least 5 years, there was a
male predominance in the high dose levodopa group. [6] In another study by
Lyons et al., men with disease duration of greater than 5 years were taking
significantly higher daily doses of levodopa compared to women of similar disease
duration, but this sex difference was not present in subjects with disease duration
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medication use in men versus women with PD, there is no clear consensus on
whether choice of dopaminergic medication is influenced by sex in the early stages
of PD.
The type and dose of dopaminergic medication can affect the rate of
development of motor complications. For example, a previous study showed that
patients randomized to levodopa developed motor fluctuations at higher rates
than those first treated with a dopamine agonist. [8] Moreover, the levodopa daily
dose used in early PD may impact the development of motor complications.
Indeed, participants in the Earlier versus Later Levodopa Therapy in Parkinson
Disease study receiving the highest levodopa doses had a higher risk of developing
dyskinesias. [9] To our knowledge, there are no prior studies examining the
specific types of dopaminergic medications used between men and women with
early PD. Knowledge of differential exposure to dopaminergic medications
according to sex could inform future clinical management. The objective of this
secondary data analysis was to examine sex influences on treatment by comparing
the type of dopaminergic medication and the levodopa equivalent daily dose
(LEDD) between men and women using baseline data from early treated PD
patients who were enrolled in the National Institute of Neurological Disorders
and Stroke Exploratory Trials in Parkinson Disease (NINDS NET-PD) Long-
Term Study-1 (LS-1). [10]
Methods
The NINDS NET-PD LS-1 is a randomized, multicenter, double-blind study of 10
grams of oral creatine/day versus matching placebo in adults with early treated PD
enrolled within five years of PD diagnosis (clinicaltrials.gov identifier#
NCT00449865). [10] The LS-1 study enrolled 1,741 participants from 45 sites in
the United States and Canada between March 13, 2007 and May 28, 2010. The
study protocol was approved by the NINDS NET-PD LS-1 Steering Committee
and Research Subjects Review Board of the University of Rochester. In addition,
an institutional review board (IRB) from each participating site approved the
study protocol and written informed consent was obtained from each study
participant. [10] Participating sites/IRBs included: University of Alabama-
Birmingham, University of South Florida, University of Southern California,
Emory University School of Medicine, Oregon Health & Science University,
University of Colorado, Johns Hopkins University, University of Texas
Southwestern Medical Center, University of California San Francisco, University
of Florida, Duke University, Louisiana State University Health Science Center-
Shreveport, Michigan State University, Rush University Medical Center,
University of Calgary, University of Pennsylvania, Beth Israel Deaconess Medical
Center, Southern Illinois University, University of Michigan, Brigham and
Women’s Hospital, University of Miami, Medical University of South Carolina,
Pacific Health Research and Education Institute, University of Alberta,
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Vermont, Northwestern University, University of Kansas Medical Center,
University of Kentucky, Dartmouth Hitchcock Medical Center, SUNY Downstate
Medical Center, Thomas Jefferson University, Baylor College of Medicine,
Georgia Health Sciences University, Institute for Neurodegenerative Disorders-
New Haven, The Parkinson’s & Movement Disorder Institute-Fountain Valley,
University of Virginia, Vanderbilt University Medical Center, Barrow
Neurological Institute, UMDNJ Robert Wood Johnson Medical School, Malcolm
Randall VA Medical Center, University of Florida-Jacksonville, Indiana University
School of Medicine, and North Shore University Health System Research
Institute. [10]
We considered the following hypotheses: 1.) there are sex differences in the
proportions of type of dopaminergic medication at baseline and 2.) there are sex
differences in the means of the LEDD at baseline. Two outcome variables were
considered for this study: type of dopaminergic medication and LEDD at baseline
for NINDS NET-PD LS-1.
Pre-planned adjusting factors (for LEDD) at baseline included: disease duration
(years since PD diagnosis), disease severity (Unified Parkinson’s Disease Rating
Scale (UPDRS) Motor + Activities of Daily Living (ADL) Scores), and body
weight. Originally, six categories were identified in the type of dopaminergic
medication used at enrollment of LS-1 participants: 1. levodopa alone; 2. levodopa
+ other medication (different from dopamine agonist), 3. dopamine agonist
alone, 4. dopamine agonist + other medication (different from levodopa), 5.
dopamine agonist + levodopa, and 6. other medication (rasagiline or
trihexyphenidyl). These six categories were used when testing the hypothesis of
differences between men and women in the type of dopaminergic medication
taken at baseline. For testing the hypothesis of differences in the LEDD between
men and women, we collapsed PD treatment into three main groups similar to the
previously published baseline LS-1 results paper [10]: levodopa alone, dopamine
agonist alone, and more than one PD medication.
Statistical Methods
Descriptive statistics of demographic characteristics, age at symptom onset and
age at PD diagnosis, as well as motor symptoms were estimated as means or
proportions. The comparison of age and motor symptoms between men and
women were estimated using t-statistics or the global O’brien non-parametric
rank sum test. The proportion of type of dopaminergic medication between men
and women was compared using a chi-square statistic. The LEDD was computed
using the method described by Tomlinson [11] with a minor modification: LEDD
calculation for Stalevo was Levodopa dose 61.33. Following the recommendation
of the Box-Cox transformation method, LEDD was transformed using the natural
logarithm (Ln) to improve normality. [12] The median and the interquartile
range (IQR) of the LEDD for men and women are reported by type of
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presented as well as for the Ln LEDD at baseline in the NINDS NET-PD LS-1 to
facilitate the clinical understanding of LEDD in the original scale and the
transformed variable. The median LEDD between men and women was compared
using a two-tailed median two sample test. Using a linear regression model, we
explored the differences in the natural logarithm of LEDD between men and
women adjusted for body weight, disease duration (years since PD diagnosis), and
disease severity (UPDRS motor + ADL). Ten participants with missing LEDD,
UPDRS motor or ADL scores were excluded from the LEDD analysis. A type I
error level value of 0.05 or less was established a priori as significant.
The natural logarithm of LEDD was adjusted on two sets of pre-planned
covariates. The first model included sex, years since PD diagnosis, body weight
and UPDRS motor + ADL scores. The second model included sex, years since PD
diagnosis, and body weight. The UPDRS motor + ADL scores were divided by 10
to be able to visualize the regression coefficient estimates with 4 decimal places.
Partial F-test statistics were used to compare model 1 and 2.
Results
On average, the LS-1 baseline cohort had mild motor impairment and a mean age
of 61.8 years. [10] There were a greater proportion of men (64.5%) than women
enrolled in the study. [10] Men and women in LS-1 had overall similar
demographic and clinical characteristics at baseline. The percentage of women
with a mean age above 50 was 86.6% compared to 90% of men. The largest ethnic
category of participants was non-hispanic whites (90.1% of men and 90.5% of
women). There were similarities in educational background with 79.2% of women
attaining some college education or higher educational status compared to 84.2%
of men.
We did not observe statistically significant differences in the mean age at first
PD symptom onset between women (58.1, standard deviation(SD)510.4) and
men (58.7, SD59.6), t-statistic for unequal variances521.27, df51186.3, p-
value50.20; or in the mean age at PD diagnosis in women (59.8, SD510.1) and
men (60.5, SD59.4), t-statistic for unequal variances 521.37, df51191.7, p-
value50.17. There were no statistically significant differences between men and
women with regard to motor signs present at baseline: resting tremor (women:
82.8%, men: 78%), rigidity (women: 86.5%, men: 87.5%), bradykinesia (women:
91.9%, men: 91.6%), postural instability (women: 20.7%, men: 18.5%) and other
motor symptoms (women: 17.9%, men516.9%), global O’Brien nonparametric
rank sum test, F53.3, df51675, p-value50.0693. The mean (SD) UPDRS motor
score for women was 17 (8.6) compared to 18.2 (8.2) for men (t-statistic for equal
variances52.97, df51731, p-value50.003).
Table 1 shows the frequency distribution of dopaminergic medication at
baseline in men and women. Among women, almost 28% were taking levodopa
alone, 27% were taking dopamine agonist alone, 19% were taking the
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agonist and other medication different from levodopa, 8% were taking levodopa
and other medication different from dopamine agonist and 0.5% were taking
other medications different from levodopa or dopamine agonist. Similar
percentages were observed among men and we did not observe statistically
significant differences in the proportions of PD dopaminergic medication used at
baseline between men and women (Chi-square statistic53.61, df55, p-
value50.61).
Table 2 shows the sample size, the median, and the interquartile range (IQR) of
the LEDD by sex and type of dopaminergic medication. The mean and standard
deviation of the Ln LEDD is also shown in Table 2. Fig. 1 displays the box plot of
Ln LEDD by sex. The unadjusted median LEDD at baseline was 300 mg
(IQR5230) for women versus 325 mg for men (IQR5240 mg) (data not shown).
We detected a significant difference in the median unadjusted LEDD between men
and women (median two sample test5282.46, two sided p-value50.0066).
However, after adjusting the Ln LEDD for body weight, disease duration (years
since PD diagnosis), and disease severity (UPDRS motor +ADL), this difference
was no longer significant (Table 3).
Discussion
While sex differences have been shown in treatment and clinical outcomes in
cardiovascular disease, pain and stroke [1,2,3], there has been little research on
the impact of sex on treatment in other prevalent conditions including PD.
Whether male or female sex impacts the type and dose of dopaminergic
medication used in PD is poorly understood. Sex differences in the clinical
characteristics described in the Parkinson’s literature including initial presenting
sign, severity of motor signs and/or development of dyskinesias [4,5] are factors
that may influence prescriber choice of dopaminergic medication in early PD.
Improved understanding of sex influences on dopaminergic medication use can
Table 1. Type of PD dopaminergic medication use at baseline: descriptive statistics and test.
Type of PD Dopaminergic medication Female Male
n% n%
Levodopa only 173 28.0 332 29.6
Levodopa + Other* (different from dopamine agonist) 52 8.4 114 10.2
Dopamine agonist alone 167 27.0 296 26.4
Dopamine agonist + Other* (different from Levodopa) 104 16.8 178 15.9
Dopamine agonist + Levodopa 119 19.3 201 17.9
Other* (different from Levodopa or dopamine agonist) 3 0.5 2 0.2
Chi-square statistic53.61, degrees of freedom55, p-value50.6054.
*Other medications included rasagiline or trihexyphenidyl.
doi:10.1371/journal.pone.0112287.t001
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patient outcomes.
Nyholm et al [6] reported that men used larger levodopa doses than women.
This study was based on estimated levodopa daily doses of subjects selected from a
national drug registry without a confirmed PD diagnosis, and without adjusting
for PD disease duration or body weight. [6] In their subsequent retrospective
chart review of 47 PD patients with a disease duration of at least 5 years, there was
a male predominance in the high-dose levodopa group. [6] In another study,
Lyons et al. reviewed database entries of 630 patients from a single center’s
Table 2. Summary statistics of the levodopa equivalent daily dose (LEDD) and natural logarithm LEDD (Ln LEDD) at baseline.
Sex Type of dopaminergic medication at baseline n LEDD (mg) Ln LEDD
Median Interquartile Range Mean SD
Female Levodopa alone 172 300 100 5.85 0.43
Dopamine agonist alone 165 180 90 5.13 0.64
More than one PD medication 277 400 275 5.96 0.53
Male Levodopa alone 330 399 250 5.98 0.44
Dopamine agonist alone 294 180 150 5.22 0.61
More than one PD medication 493 400 255.5 6.00 0.52
doi:10.1371/journal.pone.0112287.t002
Fig. 1. Box Plot: Natural logarithm of levodopa equivalent daily dose displayed by sex.
doi:10.1371/journal.pone.0112287.g001
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daily levodopa dosage using Spearman rank order correlations. [7] They reported
higher levodopa use in men versus women with PD disease duration greater than
5 years; however, this difference was not present in subjects with disease duration
less than 5 years. [7] Using the large NINDS NET-PD LS-1 study, we did not find
differences in the use of different types of dopaminergic medications between men
and women with early PD. In addition, there were no significant differences in
LEDD between men and women after controlling for body weight, disease
duration and disease severity.
While we found a significant difference in the unadjusted LEDD between men
and women (unadjusted median LEDD at baseline was 300 mg for women versus
325 mg for men, two sided p-value50.0066), this difference was no longer
significant after adjusting for several important variables. Compared to our
analysis, the previous studies by Lyons and Nyholm et al. did not adjust for
potentially confounding factors to levodopa dose including body weight. In an
analysis of levodopa treatment in the DATATOP study which accounted for body
weight, women were reported to be treated with higher levodopa doses in mg/kg
compared to men. [13,14] Weight differences can influence the pharmacokinetics
of levodopa. [15] Zappia et al. showed that the plasma levodopa area under the
curve was significantly and inversely correlated with body weight in PD patients.
[15] The impact of body weight on levodopa usage by sex is unclear as most
specialists do not prescribe based on body weight; however, previous studies
suggest that weight differences may influence sex differences in treatment response
(i.e. increased prevalence of dyskinesia in women). [15] This observation has been
previously confirmed in a study comparing levodopa-carbidopa with levodopa-
carbidopa-entacapone where low body weight and female sex were both associated
with an increased risk of dyskinesia. [16] Future studies examining sex influences
on the use of dopaminergic medications in PD should take into consideration the
potential impact of body weight on treatment dose.
We did not observe sex differences in the use of dopaminergic medications in
early PD subjects in the LS-1 study. Our analysis was based on baseline data from
a clinical trial of 1,741 PD participants from 45 sites in the U.S. and Canada and
Table 3. Ln (Levodopa equivalent daily dose) regressed on sex, years since PD diagnosis, body weight, and UPDRS motor +ADL Scores.
Model 1 Model 2
Effect Parameter estimate Standard error p-value Parameter estimate Standard error p-value
Intercept 5.437 0.083 ,.0001 5.437 0.077 ,.0001
Male 0.028 0.036 0.439 0.028 0.036 0.437
Years since PD diagnosis 0.027 0.014 0.053 0.027 0.014 0.050
Body Weight (kg) 0.003 0.001 0.001 0.003 0.001 0.001
UPDRS motor +ADL Score* 0.0003 0.014 0.985
*UPDRS motor +ADL scores were divided by 10 to visualize the regression coefficient.
Model 1 vs Model 2, Partial F test (1,1723)50.00033, p-value50.986, Model 2 is preferred.
doi:10.1371/journal.pone.0112287.t003
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method with adjustment for important confounding variables. We used levodopa
equivalent daily dose in our analysis instead of levodopa dose alone, which
allowed for a more comprehensive assessment of dopaminergic medication use in
these early PD participants.
The role of prescriber choice of dopaminergic medication based on the sex of
the patient is unclear and was not a specific focus of our study. Generally, it is
assumed that physicians, including movement disorder specialists prescribe
dopaminergic medications based on PD symptoms, disease severity, and
medication side effects. Sex differences in clinical characteristics at first
presentation and in the development of dyskinesia play an important role in
prescriber treatment choice; however, men and women in this study had overall
similar clinical characteristics at baseline including motor PD signs and prevalence
of dyskinesia.
Menopausal status and estrogen replacement therapy in women may influence
the severity of PD [14,17] and thus may influence dopaminergic medication use.
There are conflicting results on the impact of estrogen use on PD symptom
severity, with some studies showing that estrogen use may be associated with
improved motor symptoms while other studies report worsened parkinsonism
with estrogen therapy. [18,19,20] NET-PD LS-1 did not systematically collect
data on menopausal status, estrogen therapy use or hormone replacement
therapies. Future studies examining sex differences in PD should consider the
potential impact of menopausal status and estrogen therapy on dopaminergic
medication use.
It has been reported previously that socioeconomic status influences level of
utilization of medical treatment. [21] While there is a potential role of
socioeconomic status (SES) on use of dopaminergic medication in PD, we
observed similarities between men and women in educational level, an important
component of SES. Further research is warranted to clarify the impact of
socioeconomic measures on dopaminergic medication use in early PD.
Our study findings are relevant to clinical care as the type and dose of
dopaminergic medication have long-term implications for motor function and
quality of life. The large sample size and broad recruitment suggests that our
results may be generalizable to the early PD population in North America with
similar demographic characteristics as participants in LS-1; however, these results
are not generalizable to all PD treatment centers. We did not observe significant
differences between men and women in the type and dose of dopaminergic
medication in participants with early PD in the LS-1 study. Further research is
needed to understand sex influences on dopaminergic medication use in more
advanced PD and the potential impact on clinical outcomes.
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